Stockreport

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Tenax Therapeutics, Inc.  (TENX) 
Last tenax therapeutics, inc. earnings: 11/14 04:31 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.tenaxthera.com
PDF Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure wit [Read more]